enGene (NASDAQ:ENGN) Earns Overweight Rating from Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of enGene (NASDAQ:ENGN) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued an overweight rating and a $30.00 target price on the stock.

Several other analysts have also recently issued reports on the stock. Guggenheim began coverage on shares of enGene in a research report on Monday, April 15th. They set a buy rating and a $34.00 target price on the stock. SVB Leerink assumed coverage on shares of enGene in a research report on Tuesday, February 20th. They issued an outperform rating and a $31.00 price objective on the stock. Morgan Stanley assumed coverage on shares of enGene in a research report on Friday, March 8th. They set an overweight rating and a $40.00 target price on the stock. Leerink Partnrs reaffirmed an outperform rating on shares of enGene in a research report on Tuesday, February 20th. Finally, UBS Group began coverage on shares of enGene in a research note on Thursday, March 28th. They set a buy rating and a $37.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of Buy and a consensus target price of $34.40.

enGene Stock Performance

Shares of NASDAQ ENGN opened at $14.75 on Monday. The firm’s 50-day simple moving average is $16.23. enGene has a 12-month low of $6.69 and a 12-month high of $43.00.

Insider Activity

In other news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $15.01, for a total value of $68,670.75. Following the sale, the insider now owns 3,084,107 shares in the company, valued at $46,292,446.07. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional Trading of enGene

Several institutional investors have recently modified their holdings of ENGN. Fcpm Iii Services B.V. acquired a new position in enGene during the fourth quarter worth about $80,097,000. BVF Inc. IL purchased a new stake in shares of enGene in the 4th quarter valued at approximately $20,777,000. Omega Fund Management LLC purchased a new stake in shares of enGene in the 4th quarter valued at approximately $10,441,000. Finally, Vivo Capital LLC purchased a new stake in shares of enGene in the 4th quarter valued at approximately $6,264,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.